All 9 Insurance posts we have indexed from venture capital blogs and newsletters, plus the highest-scoring pieces of the past year and the people who write about it most.
P&C insurers face massive underpriced exposure to AI-enabled cyberattacks—from grid takeovers to bank data theft to ransomware—and most are doubling down on risky coverage to avoid missing the AI economy rather than honestly assessing what they don't understand.
Employer-sponsored health insurance is ripe for disruption as rising costs force employers to shop, AI reduces operational barriers, and consumers demand better experiences. Challenger health plans competing across underwriting, care navigation, and admin efficiency represent a generational replacement opportunity.
As autonomous systems and AI agents make real-time decisions without human intermediaries, traditional insurance underwriting breaks down. A new model—trace-economic underwriting using AI telemetry and parametric triggers—could price individual actions, forcing founders to build systems that are fundamentally insurable.
When AI systems fail silently in production—drifting undetected, executing errors at machine speed, or cascading through multi-agent networks—the cost of deployment becomes not just licensing but insurance. Risk has become machine-readable and machine-triggered, creating a new economy where AI viability hinges on underwritability.
As autonomous AI systems take over business operations, traditional insurance breaks down—concentration in three LLM providers creates correlated systemic risk, while silent model drift produces losses too gradual to trigger coverage. A new insurance infrastructure is emerging to price AI-specific failure modes.
Enterprise AI adoption hinges on warranty and insurance coverage—who's liable when AI fails? Model providers' indemnification programs have narrow carve-outs; specialist AI insurance (covering hallucination, agent errors) is emerging as the critical differentiator for production AI deployments.
Accelerant, an insurance MGA platform, is returning to private equity after a year public at roughly IPO price. The deal suggests bearish market consensus on Accelerant's adverse-selection-laden business model is correct, yet Thoma Bravo's willingness to pay a premium despite widespread software underperformance raises questions about either hidden value or miscalculation.
Pharmacy benefit managers (PBMs) have captured regulatory oversight, leading Trump's FTC chair to issue them favorable treatment despite their role in raising drug prices—a case study in regulatory capture within healthcare.
Ian's Blog: Nominal Returns (4) · Amir Kabir (4) · Net Interest (3) · Foundation Capital (1) · BIG by Matt Stoller (1) · yCombinator (1) · Newcomer (1) · Madrona Ventures (1) · Chamath Palihapitiya (1) · Michael Greeley (1)
Suggest a blog or newsletter for the SandHill index. We track the RSS feed and feature the best pieces in the weekly digest.
The latest theses & analyses from 800+ venture investors, curated into one email. Join 5,000+ investors, founders and LPs.